Search Results

You are looking at 51 - 60 of 91 items for :

  • Refine by Access: All Content x
Clear All

studies showing no benefit and greater discontinuation rates (30%) compared to placebo (17%), hypothesized to be secondary to unreported adverse effects ( Friedman et al., 2007 ). Given these limitations, novel therapeutics, such as MDMA

Open access

Introduction In the past decade, novel psychoactive substances (NPSs) gained a significant role on the contemporary drug scene. With a decreasing purity and availability of 3,4-methyl​enedioxy​methamphetamine (MDMA), cocaine

Open access

World Religions , 3 ( 2019 ), 81 – 103 . http://doi.org/10.1556/2054.2019.012 . Roberts T. (Ed.). ( 2020 ). Psychedelics and spirituality: The sacred use of LSD, psilocybin, and MDMA for human transformation . Rochester, VT : Park Street Press

Open access

(MDMA/ecstasy) use (variable ECSFLAG for 2013–2014 and ECSTMOFLAG for 2015–2019; 0 = never used, 1 = ever used), and lifetime inhalant use (variable INHFLAG for 2013–2014 and INHALFLAG for 2015–2019; 0 = never used, 1 = ever used). All covariates were

Open access

, 2021 , 39:53). This confidence in the notion that psychedelics will radically minimize interpersonal harms reappears in another frequent slogan: “I believe that fully globalized access to MDMA-assisted therapy can lead to a world of net-zero trauma by

Open access

MDMA, which makes sense given that components include elemicin, eugenol, and safrole ( Nowak, Woźniakiewicz, Gładysz, Sowa, & Kościelniak, 2016 ). All of these are related to MDMA, and are found in the Holy Ointment. Furthermore, potent

Open access

maltreatment ( Healy, Lee, & D’Andrea, 2021 ). This finding suggests that psychedelics may reduce the impact of a history of adverse childhood experiences (ACEs) on distress in adulthood. In addition, a randomized, double-blind, placebo-controlled study of MDMA

Open access
Journal of Psychedelic Studies
Authors:
Kelley C. O’Donnell
,
Sarah E. Mennenga
, and
Michael P. Bogenschutz

participants with any use of psychedelics (including psilocybin, MDMA, LSD, mescaline, DMT, and other similar hallucinogenic compounds) within the last year at a minimum. Excluding use for the past 5 years may be appropriate for some study designs. However

Open access

findings are consistent with prior studies showing that MDMA, a serotonergic psychedelic, has been shown to produce significant PTSD symptom reduction ( Ot’alora G et al., 2018 ). Additionally, animal studies have shown that ibogaine was effective in

Open access

The effect of group-administered psilocybin on psychological flexibility and outcomes Research on the efficacy of psychedelic-assisted therapy (PAT) has expanded rapidly in the last decade. The FDA has designated breakthrough therapy status for MDMA

Open access